rare cancer

ANZGOG subgroup study of ovarian and breast cancer patients EMBRACE closes to recruitment

EMBRACE is a Phase II clinical trial of the PARP inhibitor, olaparib, in HR-deficient metastatic breast and relapsed ovarian cancer in patients without germline mutations in BRCA1 and BRCA2. Dr Katrin Sjoquist, Medical Oncologist [...]

ANZGOG subgroup study of ovarian and breast cancer patients EMBRACE closes to recruitment2022-07-01T11:34:46+10:00

ANZGOG Director awarded for her significant contribution as a medical oncology clinician

ANZGOG Director Professor Clare Scott has been awarded the Medical Oncology Group of Australia (MOGA) and Novartis Oncology Cancer Achievement Award. Professor Clare Scott, Medical Oncologist Prof Clare Scott is a clinical [...]

ANZGOG Director awarded for her significant contribution as a medical oncology clinician2021-11-10T23:05:11+11:00
Go to Top